Imaavy

Imaavy (nipocalimab-aahu) has become the first approved treatment for warm autoimmune hemolytic anemia, a rare condition in which the immune system destroys red blood cells. Observers in the science and biotech community are calling it a significant win for the treatment of orphan diseases, noting that patients with wAIHA previously had no approved dedicated therapy. Approval of a drug for such a small patient population highlights growing momentum in rare disease drug development.